So we’re very much looking forward to the Phase 3 results and I think there’s going to be, if the results come out as we expect them to, a high level of enthusiasm for vanzacaftor.
Michael Yee: Super helpful. Just to clarify on the QT, that was a study that’s up, is that, can you say that that was completed and all set? Yes, nothing new to report there. This is a, — QT is a study we do for cardiac function. It’s 1 of our standard studies that we do in the clinical pharmacology realm.
Michael Yee: Got it. Thank you.
Susie Lisa: Last question, please, Chuck.
Operator: The last question will come from Terence Flynn with Morgan Stanley. Please go ahead.
Terence Flynn: Hi, thanks for taking the questions. I was just wondering if, let’s say the theoretical situation where one of the randomized controlled Phase 3 acute trials is positive and the other is not, Can you still file for approval in that data set or do you need two positive trials? And then Stuart, I just wondered if you could clarify your comments on 2024 being a foundational year for exa-cell. What that means? Does that mean you’re comfortable with consensus where it stands or you think it’s going to be somewhat more measured launch? Just want to clarify what foundational means. Thank you.
Reshma Kewalramani: Yeah. Hey, Terence, this is Reshma. Let me comment on acute pain and then I’ll turn it over to Stuart. You know, we are very close to having the results from the acute pain program, and I’ll just leave it at, our goal is to have a positive set of three studies, and our goal is to file for a broad, moderate to severe acute pain label. Stuart?
Stuart Arbuckle: Yeah, and on exa-cel and the comment we made about it being a foundational year that has nothing to do with consensus. I actually couldn’t tell you what consensus is for 2024 for exa-cel to be perfectly honest with you Terence. It was really a response, we’ve been asked a lot of questions about what the launch dynamics will look like for exa-cel. And so we thought it was important to remind people of what the patient journey is. And that’s obviously going to begin, hopefully, later this year when we get regulatory approval. And it was really to try and provide some context around that multi-stage journey that patients need to go through to get exa-cel. So that was really the reasons for the comment. It was responding to questions we’ve had about launch dynamics.
I do want to reiterate something which I said in my prepared remarks as well. Whatever the journey to get there, we see this as being a very large commercial opportunity. There are tens of thousands of patients with severe sickle cell disease and beta thalassemia who could benefit. Despite the journey being relatively long, this is a journey at the end of it that has the potential for a lifetime of benefit. So we feel very optimistic about the exa-cel opportunity and we’re looking forward to launching.
Susie Lisa: Thanks, Jack. If you could give the details, please, for callback.
Operator: Yes, ma’am. Replay of today’s event will be available shortly after the call concludes by dialing 1-877-344-7529 or 1-412-317-0088, using the replay access code 2047491. The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.
